<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537601</url>
  </required_header>
  <id_info>
    <org_study_id>2012/CHR/01</org_study_id>
    <nct_id>NCT01537601</nct_id>
  </id_info>
  <brief_title>CIRCumcision and Urinary Tract Infections in Boys With Posterior Urethral Valves</brief_title>
  <acronym>CIRCUP</acronym>
  <official_title>Effect of Circumcision on the Risk of Febrile Urinary Tract Infections in Children With Posterior Urethral Valves.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de la Réunion</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de la Réunion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children with posterior urethral valves (PUV) are at risk of presenting febrile urinary tract
      infections (UTI). Circumcision has been shown to decrease the number of febrile UTIs in
      healthy children. The effect of circumcision on the number of UTIs in boys with PUV has not
      yet been studied. Through a prospective randomised trial of children with posterior urethral
      valves the investigators wish to determine the effect of circumcision on the risk of
      presenting febrile UTIs. One group will be on antibiotic prophylaxis alone and the other will
      be on antibiotic prophylaxis plus circumcision performed at the time of valve resection. Both
      groups will be followed for two years, with clinical examination at 1, 3, 6, 12, 18 and 24
      months. A DMSA scan will be performed at 1-2 and 24 months and biological renal function will
      also be monitored. The relative risk of presenting a febrile UTI in each group will be
      determined. Clinical, radiological and antenatal data concerning each child will be analysed.
      At 24 months follow-up, an &quot;impact on family scale&quot; survey (IOFS) will be proposed parents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After diagnosis of posterior urethral valves, children will be randomised either to
      antibioprophylaxis alone or antibioprophylaxis plus circumcision. Circumcision will be
      performed at the time of valve resection. Children will undergo a cystogram between 1 and 4
      months to control valve resection. They will be followed for two years and the number of
      febrile UTIs in each group will be compared. The diagnosis of febrile UTI will be confirmed
      by urethral catheterisation or suprapubic aspiration. A DMSA scan will be performed at the
      beginning and end of the study to determine whether children who have presented febrile UTIs
      show deterioration of their DMSA as compared to those who did not present febrile UTIs.

      At 24 months follow-up, &quot;impact on family scale&quot; survey (IOFS) whose main objective is to
      evaluate the impact of family support for a child with posterior urethral valves will be
      proposed parents.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2012</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative risk of presenting a febrile UTI</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of children with febrile UTIs in each group at two years</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of compliance to antibioprophylaxis.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the grade of reflux</measure>
    <time_frame>At diagnosis and at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the number of children who will show deterioration of their DMSA scan between children who have had UTIs and those who have not.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number and type of adverse effects related to circumcision and antibiotic prophylaxis</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of the responsible bacteria</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Posterior Urethral Valves</condition>
  <arm_group>
    <arm_group_label>Antibiotic prophylaxis alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Children will be on antibioprophylaxis and will not have a circumcision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Circumcision and antibiotic prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children will have a circumcision at the time of valve resection and will be on antibioprophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Circumcision</intervention_name>
    <description>Circumcision</description>
    <arm_group_label>Circumcision and antibiotic prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antibiotic prophylaxis alone</intervention_name>
    <description>Antibiotic prophylaxis alone</description>
    <arm_group_label>Antibiotic prophylaxis alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male

          -  aged 0 to 28 days

          -  diagnosed with posterior urethral valves within the 28 first day of life

          -  holders of parental authority affiliated to French national health insurance

          -  informed consent signed by holders of parental authority

        Exclusion Criteria:

          -  boys with hypospadias or epispadias or any other anomaly rendering circumcision
             impossible

          -  concomitant participation to another clinical trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédérique Sauvat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional Hospital Reunion Island - Felix Guyon Site</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Dobremez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Bordeaux, Hôpital Pellegrin Enfants</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Fourcade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Limoges - Hôpital de la mère et de l'enfant</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas Kalfa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Montpellier - Hôpital Lapeyronie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frédéric Auber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU St Jacques - Besançon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benjamin Frémond</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alaa El Ghoneimi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Robert Debré</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Blanc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Necker Enfants Malades</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Michel Guys, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital d'enfants de la Timone, Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thierry Merrot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nord, Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc David Leclair, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georges Audry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Armand Trousseau, Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Laurence Poli-merol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Reims</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of pediatric surgery, Bordeaux hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Woolf AS, Thiruchelvam N. Congenital obstructive uropathy: its origin and contribution to end-stage renal disease in children. Adv Ren Replace Ther. 2001 Jul;8(3):157-63. Review.</citation>
    <PMID>11533916</PMID>
  </reference>
  <reference>
    <citation>Parkhouse HF, Barratt TM, Dillon MJ, Duffy PG, Fay J, Ransley PG, Woodhouse CR, Williams DI. Long-term outcome of boys with posterior urethral valves. Br J Urol. 1988 Jul;62(1):59-62.</citation>
    <PMID>3408870</PMID>
  </reference>
  <reference>
    <citation>Singh-Grewal D, Macdessi J, Craig J. Circumcision for the prevention of urinary tract infection in boys: a systematic review of randomised trials and observational studies. Arch Dis Child. 2005 Aug;90(8):853-8. Epub 2005 May 12. Review.</citation>
    <PMID>15890696</PMID>
  </reference>
  <reference>
    <citation>Simforoosh N, Tabibi A, Khalili SA, Soltani MH, Afjehi A, Aalami F, Bodoohi H. Neonatal circumcision reduces the incidence of asymptomatic urinary tract infection: a large prospective study with long-term follow up using Plastibell. J Pediatr Urol. 2012 Jun;8(3):320-3. doi: 10.1016/j.jpurol.2010.10.008. Epub 2010 Nov 5.</citation>
    <PMID>21115400</PMID>
  </reference>
  <reference>
    <citation>Mukherjee S, Joshi A, Carroll D, Chandran H, Parashar K, McCarthy L. What is the effect of circumcision on risk of urinary tract infection in boys with posterior urethral valves? J Pediatr Surg. 2009 Feb;44(2):417-21. doi: 10.1016/j.jpedsurg.2008.10.102.</citation>
    <PMID>19231547</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2012</study_first_submitted>
  <study_first_submitted_qc>February 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2012</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Posterior urethral valves</keyword>
  <keyword>Febrile urinary tract infection</keyword>
  <keyword>Circumcision</keyword>
  <keyword>Antibioprophylaxis</keyword>
  <keyword>Impact on family</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

